Page 4 - Slide 1
P. 4
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1026 Blosozumab, a Humanized Monoclonal Antibody
against sclerostin, demonstrated Anabolic Effects on
Bone in Postmenopausal Women.
McColm J, Womack T, Hu L, et al.
Session: Concurrent Oral Session 05: John H. Carsten's
Memorial Session for Osteoporosis Treatment ◼
Saturday , October 13 09:45 AM - 10:00 AM ◼
Auditorium-Main/Minneapolis Convention Center
Abstract Information Additional Notes from
Poster/Presentation*
Backgro ▪ This report presents results of two
und phase 1 studies on the safety, Strengths, Weaknesses, Key
tolerability, PK/PD and Points
immunogenicity of single and
multiple escalating doses of
blosozumab in PM women
Methods ▪ Both the studies were subject- and
investigator-blind, placebo-
controlled, randomized studies in
PM women on prior/ current ALN
usage.
▪ The single dose study involved 8
subjects, who were administered
single IV doses up to 750 mg,
single SC dose of 150 mg.
▪ The multiple dose study involved
12 subjects, who were
administered multiple IV doses up
to 750 mg Q2W and multiple SC
doses up to 270 mg Q2W.
▪ Assessments were done for up to
12 weeks after the final dose.
* Assignment notes will be collected at the Amgen Mentoring Program Debrief Meeting. Hardcopy or Electronic versions are acceptable
